Insmed (INSM) Accumulated Expenses (2010 - 2024)
Insmed (INSM) posted quarterly Accumulated Expenses of $248.7 million for Q3 2024, up 32.43% year-over-year from $187.8 million in Q4 2023, and down 14.5% quarter-over-quarter from $290.8 million in Q2 2024.
Insmed (INSM) Accumulated Expenses (2010 - 2024) Analysis & Trends
Insmed's Accumulated Expenses history runs 15 years deep, the most recent figure standing at $248.7 million for Q3 2024.
- In Q3 2024, Accumulated Expenses rose 32.43% year-over-year to $248.7 million; the TTM figure through Sep 2024 stood at $248.7 million (up 32.43% YoY), while the FY2023 annual figure was $215.0 million, up 18.05% from the prior year.
- Accumulated Expenses for Q3 2024 stood at $248.7 million, down from $290.8 million in the prior quarter.
- The five-year high for Accumulated Expenses was $290.8 million in Q2 2024, with the low at $8.9 million in Q1 2020.
- The 5-year median for Accumulated Expenses is $125.0 million (2021), against an average of $114.6 million.
- The sharpest annual moves came in 2020 and 2023: Accumulated Expenses slumped 76.64% in 2020, then soared 1212.45% in 2023.
- Insmed's Accumulated Expenses stood at $25.6 million in 2020, then soared by 388.57% to $125.0 million in 2021, then jumped by 45.66% to $182.1 million in 2022, then gained by 18.05% to $215.0 million in 2023, then climbed by 15.67% to $248.7 million in 2024.
- Business Quant data shows INSM's Accumulated Expenses at $248.7 million in Q3 2024, $290.8 million in Q2 2024, and $189.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 248.68 Mn |
| Jun 30, 2024 | 290.84 Mn |
| Mar 31, 2024 | 189.36 Mn |
| Dec 31, 2023 | 214.99 Mn |
| Sep 30, 2023 | 187.78 Mn |
| Jun 30, 2023 | 197.65 Mn |
| Mar 31, 2023 | 179.01 Mn |
| Dec 31, 2022 | 182.12 Mn |
| Sep 30, 2022 | 131.86 Mn |
| Jun 30, 2022 | 58.77 Mn |
| Mar 31, 2022 | 13.64 Mn |
| Dec 31, 2021 | 125.03 Mn |
| Sep 30, 2021 | 19.55 Mn |
| Jun 30, 2021 | 45.55 Mn |
| Mar 31, 2021 | 10.15 Mn |
| Dec 31, 2020 | 25.59 Mn |
| Sep 30, 2020 | 35.15 Mn |
| Jun 30, 2020 | 13.02 Mn |
| Mar 31, 2020 | 8.95 Mn |
| Dec 31, 2019 | 19.14 Mn |